[Biologics in current therapy for inflammatory bowel disease]
Tadakazu Hisamatsu1, Toshifumi Hibi
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University.
Summary
Biologics, like anti-tumor necrosis factor-alpha (TNFα) agents, are revolutionizing inflammatory bowel disease (IBD) treatment. Infliximab
Area of Science:
- Molecular biology and immunology advancements drive the development of biologics for inflammatory bowel disease (IBD).
- Anti-tumor necrosis factor-alpha (TNFα) agents represent a significant therapeutic innovation in IBD management.
Context:
- Traditional IBD therapeutic strategies have seen limited evolution until recent biologic advancements.
- Infliximab, the first anti-TNFα agent, has dramatically altered IBD treatment paradigms.
- The top-down treatment strategy is increasingly recognized for improving patient outcomes in Crohn's disease and rheumatoid arthritis.
Purpose:
- To review current biologic therapies for inflammatory bowel disease (IBD).
- To discuss the impact of anti-TNFα agents, specifically Infliximab, on IBD treatment.
- To explore future directions in biologic drug development for IBD.
Summary:
- The advent of biologics, exemplified by Infliximab, has transformed inflammatory bowel disease (IBD) therapy.
- Infliximab's success in treating Crohn's disease and ulcerative colitis validates the top-down treatment approach.
- This progress stimulates the development of novel anti-TNFα agents and other biologics for IBD.
Impact:
- Biologic therapies, particularly anti-TNFα agents, offer new hope for managing IBD, including pediatric cases.
- The success of Infliximab has paved the way for further innovation in IBD treatment strategies.
- Continued research into biologics promises improved patient outcomes and disease management in IBD.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...